1. S.M. Swetter, J.A. Thompson, M.R. Albertini, C.A. Barker, J. Baumgartner, G. Boland, B. Chmielowski, D. DiMaio, R.C. Fields, M.D. Fleming, A. Galan, B. Gastman, S. Guild, A. Holder, J. Hyngstrom, D. Johnson, R.W. Joseph, G. Karakousis, K. Kendra, M. Kiuru, J.R. Lange, R. Lanning, A.J. Olszanski, P.A. Ott, M.I. Ross, A.K. Salama, R. Sharma, J. Skitzki, J. Sosman, K. Tsai, Y. Xing, E. Wuthrick, N.R. McMillian, M. Nguyen, Cutaneous Melanoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf, (accessed 1 March 2023).
2. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma;Long;J. Clin. Oncol.,2011
3. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial;Ascierto;Lancet Oncol.,2016
4. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial;Long;Lancet,2015
5. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial;Dummer;Lancet Oncol.,2018